MINI FUTURE LONG - UNITED THERAPEUTICS Share Price

Certificat

DE000MG2HYC4

Market Closed - Börse Stuttgart 12:30:38 17/05/2024 am IST
8.05 EUR -0.62% Intraday chart for MINI FUTURE LONG - UNITED THERAPEUTICS
Current month+64.62%
Date Price Change
16/24/16 8.05 -0.62%
15/24/15 8.1 +5.61%
14/24/14 7.67 +4.21%
13/24/13 7.36 -0.81%
10/24/10 7.42 -1.33%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 12:30 am IST

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN MG2HYC
ISINDE000MG2HYC4
Date issued 17/04/2024
Strike 184.9 $
Maturity Unlimited
Parity 10 : 1
Emission price 4.86
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 8.16
Lowest since issue 4.43

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
272.2 USD
Average target price
292.7 USD
Spread / Average Target
+7.54%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW